Article

Evolution of resistance to KRAS <sup>G12C</sup> inhibitor in a non-small cell lung cancer responder

2023-12-20

Abstract excerpt

Despite initial therapeutic successes, most patients with non-small cell lung cancer (NSCLC) who carry the KRAS G12C mutation ultimately exhibit resistance to targeted treatments. To improve our comprehension of how acquired resistance develops, we present an unprecedented longitudinal case study profiling the transcriptome of peripheral blood mononuclear cells (PBMCs) over 5 months from an NSCLC patient with the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3b185b7c-cbff-527c-a249-4d3d49e8279d
DOI: 10.1101/2023.12.18.572090

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evolution of resistance to KRAS <sup>G12C</sup> inhibitor in a non-small cell lung cancer responderDOI 10.1101/2023.12.18.572090Read

Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responderSemantic proximity Read

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Semantic proximity Read

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Semantic proximity Read

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity Read

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.Semantic proximity Read

Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma.Semantic proximity Read

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity Read

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and <i>MET</i> amplificationSemantic proximity Read

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapiesSemantic proximity Read